FORT LEE, N.J.--(BUSINESS WIRE)--Kedrion Biopharma proudly announces that Koate® Double Viral Inactivation (DVI) Antihemophilic Factor (human) is now being manufactured using a process that further enhances the safety and purity of that product. Koate-DVI is used in the treatment of hemophilia A, a rare, inherited condition characterized by a person’s inability to form effective blood clots following an injury, and by spontaneous bleeding into one’s joints. Koate-DVI belongs to the class of products known as “plasma-derived clotting factors,” all of which are manufactured using human plasma as starting material.
Help employers find you! Check out all the jobs and post your resume.